Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesImmunology/RheumatologyAspirus Arise Tocilizumab IV Coverage Update | Ope…
    Ask Trek AI about this page
    ModifiedAspirus ArisePOLIcY: Inflammatory Conditions Tocilizumab Intravenous Products Utilization Management Medical Policy

    Inflammatory Conditions Tocilizumab Intravenous Products Utilization Management Medical Policy

    Customize your policy alerts

    Sign up for Aspirus Arise POLIcY: Inflammatory Conditions Tocilizumab Intravenous Products Utilization Management Medical Policy alerts

    Get alerted when POLIcY: Inflammatory Conditions Tocilizumab Intravenous Products Utilization Management Medical Policy changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization, coverage criteria, dosing, and specialty prescriber requirements for intravenous tocilizumab products (Actemra, Tofidence and listed biosimilars) for Aspirus Medicare plans.

    Policy Summary
    PayerAspirus Arise
    PolicyInflammatory Conditions Tocilizumab Intravenous Products Utilization Management Medical Policy
    Policy CodePolicy POLIcY: Inflammatory Conditions Tocilizumab Intravenous Products Utilization Management Medical Policy
    Change TypeMaterial revisions and clarifications (age criteria, step therapy documentation, new CRS indication)
    Effective DateJan 1, 2021
    Last ReviewMay 8, 2025
    Next Review DateMay 8, 2025
    Key ActionObtain prior authorization and provide documentation of indication-specific criteria and chart note justification when requesting a non-preferred product.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    Cytokine Release Syndrome Associated with Bispecific Antibodies was added as a condition of approval.

    Step therapy updated to require documentation of clinical need for non-preferred product over preferred biosimilars.

    Added age requirements for initial approvals for multiple indications (e.g., Giant Cell Arteritis, RA, SJIA, Castleman disease, immunotherapy-related toxicities, polymyalgia rheumatica, Still's disease).

    Acute treatment of COVID-19 in hospitalized patients is not addressed in this policy.

    All Aspirus Medicareplans governed
    Multipleindications covered
    Prior authauthorization requirement
    Tyenne preferredstep therapy preference
    8 mg/kgmax dosing
    COVID-19explicit non-recommended

    Coverage Criteria and Indications

    CRS (CAR T-cell therapy)

    Covered when ALL of the following are met

    CRS criteria: Patient has cytokine release syndrome (CRS) associated with CAR T-cell therapy and tocilizumab is prescribed for that indication

    Approve for 1 week (adequate to receive up to four doses). Dosing: if patient <30 kg, up to 12 mg/kg (maximum 800 mg per dose); if patient ≥30 kg, up to 8 mg/kg (maximum 800 mg per dose). Approve up to four doses if there will be an interval of at least 8 hours between doses.

    Giant Cell Arteritis

    Covered when ONE of the following is met

    GCA initial or continuation: Patient is ≥18 years of age AND either: (A) Initial therapy — patient has tried or is currently taking a systemic corticosteroid or corticosteroids are contraindicated, and the medication is prescribed by or in consultation with a rheumatologist; OR (B) Continuation — patient has been established on therapy for at least 6 months and meets at least ONE of: (a) beneficial clinical response by at least one objective measure from baseline; OR (b) improvement in at least one symptom compared with baseline

    Initial: approve for 6 months. Continuation: approve for 1 year if established ≥6 months. Dosing: approve up to 6 mg/kg (maximum 600 mg) with interval of at least 4 weeks between doses.

    Polyarticular JIA

    Covered when ONE of the following is met

    Polyarticular JIA initial or continuation: Patient is ≥2 years of age AND either: (A) Initial therapy — patient meets ALL initial criteria including meeting ONE of: tried one other systemic therapy (e.g., methotrexate, sulfasalazine, leflunomide, or an NSAID), or will receive tocilizumab concurrently with methotrexate/sulfasalazine/leflunomide, or has an absolute contraindication to those agents, or has aggressive disease; medication prescribed by or in consultation with a rheumatologist; OR (B) Continuation — patient has been established on therapy for at least 6 months and meets at least ONE of: (a) beneficial clinical response by objective measure from baseline; OR (b) improvement in at least one symptom compared with baseline

    Initial: approve for 6 months. Continuation: approve for 1 year if established ≥6 months. Dosing: if <30 kg, approve up to 10 mg/kg (maximum 800 mg) with interval at least 4 weeks between doses.

    Rheumatoid Arthritis

    Covered when ONE of the following is met

    RA initial or continuation: Patient is ≥18 years of age AND either: (A) Initial therapy — patient has tried ONE conventional synthetic DMARD for at least 3 months (unless exception when patient already tried a biologic) and medication is prescribed by or in consultation with a rheumatologist; OR (B) Continuation — patient has been established on therapy for at least 6 months and meets at least ONE of: (a) beneficial clinical response when assessed by at least one objective disease activity measure from baseline; OR (b) improvement in at least one symptom compared with baseline

    Dosing: approve up to 8 mg/kg (maximum 800 mg) with interval of at least 4 weeks between doses. Initial approvals and continuation approvals as specified.

    Systemic JIA / Still's disease

    Covered when ONE of the following is met

    SJIA / AOSD initial or continuation: Patient is ≥2 years of age (for SJIA) OR adult criteria for AOSD and either: (A) Initial therapy — medication prescribed by or in consultation with a rheumatologist; OR (B) Continuation — patient has been established on therapy for at least 6 months and meets at least ONE of: (a) beneficial clinical response by at least one objective measure from baseline; OR (b) improvement in at least one symptom compared with baseline

    Initial: approve for 6 months. Continuation: approve for 1 year if established ≥6 months. Dosing: if <30 kg, up to 12 mg/kg per dose; if ≥30 kg, up to 8 mg/kg per dose. Interval between doses at least 1–2 weeks depending on age/indication per prescribing criteria.

    Castleman Disease

    Covered when ALL of the following are met

    Castleman disease: Patient is ≥18 years of age AND patient is negative for HIV and HHV-8 AND medication is prescribed by or in consultation with an oncologist or hematologist AND medication is being used for relapsed or refractory disease

    Initial approval: 6 months if all initial criteria met. Continuation: approve for 1 year if established on therapy ≥6 months and meets at least ONE of: (a) beneficial clinical response by at least one objective measure from baseline (e.g., normalization/improvement of CRP, ESR, fibrinogen, albumin, hemoglobin, increased BMI, or reduction in lymphadenopathy); OR (b) improvement in at least one symptom such as resolution of constitutional symptoms or improved physical function.

    Continuation Therapy (example structure from pediatric indication)

    Covered when ALL/OR combinations described are met for continuation:

    Continuation common requirements: Patient has been established on therapy for at least 6 months AND medication is prescribed by or in consultation with a rheumatologist AND patient meets at least ONE of the following: (a) when assessed by at least one objective measure the patient experienced a beneficial clinical response from baseline; OR (b) compared with baseline the patient experienced improvement in at least one symptom (for example less pain, stiffness, fatigue, or improved function)established on therapy >=6 months

    A patient who received <6 months of therapy or is restarting therapy is reviewed under Initial Therapy criteria.

    Castleman Disease — Initial and Continuation Criteria

    Approve for specified duration if one of the following applies:

    Initial Approval for Castleman disease: Patient is ≥18 years of age AND (A) Initial approval — patient meets ALL of the following: negative for HIV and HHV-8; medication prescribed by or in consultation with an oncologist or hematologist; medication used for relapsed or refractory disease; OR (B) Continuation — patient has been established on therapy for at least 6 months and meets at least ONE of: objective clinical response by at least one measure from baseline OR improvement in at least one symptominitial 6 months

    Initial approval duration: 6 months. Continuation approval: 1 year if established ≥6 months and response criteria met.

    Cytokine Release Syndrome Associated with Bispecific Antibodies

    Covered when the following are met:

    CRS with bispecific antibodies: Prescribed for a patient who has been or will be treated with a bispecific antibody (examples listed in policy) and tocilizumab is prescribed for CRS related to that bispecific antibody1 week (adequate for up to four doses)

    Approve for 1 week to allow up to four doses. Dosing: if patient <30 kg, up to 12 mg/kg (maximum 800 mg per dose); if patient ≥30 kg, up to 8 mg/kg (maximum 800 mg per dose). There must be an interval of at least 8 hours between doses.

    Graft-Versus-Host Disease and Immunotherapy-Related Toxicities

    Covered when indication-specific criteria met:

    Graft-versus-host disease (GVHD) initial and continuation: Patient is ≥18 years of age AND Initial therapy — patient has acute GVHD, has tried at least one systemic medication for GVHD, and medication is prescribed by or in consultation with an oncologist, hematologist, or physician affiliated with a transplant center; OR Continuation — patient is currently receiving tocilizumab and has been established on therapy for at least 1 month and meets at least ONE of: beneficial clinical response by objective measure or improvement in at least one symptom compared with baselineinitial 1 month; continuation 3 months

    Initial approval: 1 month. If currently receiving tocilizumab and criteria met, approve continuation for 3 months. Examples of systemic medications include corticosteroids, antithymocyte globulin, cyclosporine, tacrolimus, mycophenolate, ruxolitinib, basiliximab, etanercept, infliximab, sirolimus, pentostatin, vedolizumab.

    Immunotherapy-related toxicities due to checkpoint inhibitors initial and continuation: Patient is ≥18 years of age AND Initial therapy — prescriber indicates patient developed an immunotherapy-related toxicity while receiving a checkpoint inhibitor and is symptomatic despite a trial of at least one systemic corticosteroid; OR Continuation — patient is currently receiving tocilizumab and has been established on therapy for at least 6 months and meets at least ONE of: beneficial clinical response by objective measure or improvement in at least one symptom compared with baseline

    Polymyalgia Rheumatica and Adult-Onset Still's Disease

    Covered when indication-specific criteria met:

    Polymyalgia rheumatica initial and continuation: Patient is ≥18 years of age AND Initial therapy — patient has tried one systemic corticosteroid (unless contraindicated) and medication is prescribed by or in consultation with a rheumatologist; OR Continuation — patient has been established on therapy for at least 6 months and meets at least ONE of: beneficial clinical response by objective measure or improvement in at least one symptom compared with baselineinitial 6 months; continuation >=6 months for review

    Initial approval when criteria met; continuation approval for 1 year if established ≥6 months and response criteria met. Dosing: approve up to 6 mg/kg (maximum 600 mg) with interval of at least 4 weeks between doses.

    Adult-onset Still's disease (AOSD): Patient is ≥18 years of age AND Initial therapy — medication prescribed by or in consultation with a rheumatologist; OR Continuation — patient has been established on this medication for at least 6 months and meets at least ONE of: beneficial clinical response by objective measure or improvement in at least one symptom compared with baselineinitial 6 months; continuation 1 year

    Initial approval: 6 months. Continuation approval: 1 year if established ≥6 months. Dosing: approve up to 8 mg/kg per dose with interval of at least 2 weeks between doses.

    The acute treatment of hospitalized patients with COVID-19 is not addressed in this policy. Prior authorization guidance and recommended indications in this document do not apply to the inpatient acute management of COVID-19.

    Use of tocilizumab for COVID-19 is generally not recommended in this policy except where explicitly described. The policy notes that tocilizumab IV is indicated only for hospitalized adults with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive ventilation, or ECMO; dosing for that indication is a single 8 mg/kg infusion (maximum 800 mg) with an optional second dose ≥8 hours later if clinically indicated.

    Concurrent administration of tocilizumab with another biologic agent or with a targeted synthetic oral small molecule drug for an inflammatory condition is not recommended. Combination biologic or targeted synthetic therapy is discouraged due to increased risk of adverse events and lack of supportive controlled data; this restriction does not apply to concomitant use of conventional synthetic DMARDs such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine.

    Coverage of tocilizumab for Crohn's disease is not recommended based on limited pilot study data. The policy cites a 12-week pilot trial that did not provide sufficient evidence of durable benefit, and states further studies are needed before coverage is supported.

    The list of indications and examples in the appendix is not exhaustive. Oncology indications and rare inflammatory conditions are not listed here; refer to the product prescribing information and emerging literature for other potential uses.

    Requests for a non-preferred tocilizumab product will be subject to step therapy rules. A non-preferred product may be approved only if the patient is not a new start to the non-preferred product within the prior 365 days, has a documented allergy or intolerance to all preferred products, has therapeutic failure of preferred products after an adequate trial, or has a diagnosis covered only by the non-preferred product. For patients new to therapy, chart documentation is required to justify use of a non-preferred product over the preferred biosimilar.

    Requests for indications or clinical circumstances not listed in the Recommended Authorization Criteria are not recommended for approval and will be considered not medically necessary until new published data are available. The policy specifically identifies COVID-19 outside the described hospitalized setting and other off-criteria uses as common denial triggers.

    Coding, Products, and Dosing Information

    Covered Indications / Clinical codesmixed
    CRS (CAR T-cell therapy)Cytokine Release Syndrome associated with Chimeric Antigen Receptor (CAR) T-Cell Therapy — approve for 1 week (adequate to receive up to four doses); weight-based dosing: <30 kg up to 12 mg/kg (max 800 mg) or ≥30 kg up to 8 mg/kg (max 800 mg); interval ≥8 hours between doses.
    Giant Cell ArteritisGiant Cell Arteritis — patient ≥18 years; initial therapy approve 6 months with trial of or contraindication to systemic corticosteroid and prescribed by/with rheumatologist; continuation approvals as specified.
    Polyarticular Juvenile Idiopathic Arthritis (PJIA)Polyarticular JIA — patient ≥2 years; initial and continuation criteria apply; pediatric dosing and limits specified in policy.
    Rheumatoid Arthritis (RA)Rheumatoid arthritis — patient ≥18 years; requires trial of conventional DMARDs or prior biologic as specified; dosing up to 8 mg/kg (max 800 mg).
    Systemic Juvenile Idiopathic Arthritis (SJIA) / Still's diseaseSystemic JIA/Still's disease — patient ≥2 years (or adult-onset for AOSD); dosing: <30 kg up to 12 mg/kg per dose or ≥30 kg up to 8 mg/kg per dose; interval and approval durations as specified.
    Castleman DiseaseCastleman disease — other use with supportive evidence; patient ≥18 years, HIV- and HHV-8-negative, relapsed/refractory disease, prescribed by/with oncologist or hematologist; initial and continuation criteria and objective response measures apply.
    Products referencedNDC | mixed
    Tyenne (biosimilar)Preferred biosimilar product added as preferred for patients new to therapy (preferred before Actemra and Tofidence).
    ActemraActemra — tocilizumab intravenous infusion product (non-preferred in step therapy).
    TofidenceTofidence — tocilizumab intravenous product (non-preferred biosimilar).
    inv-21: Weight-based dosing cutoffs
    Weight thresholdsPolicy uses <30 kg and ≥30 kg cutoffs for weight-based dosing across indications
    CRS (CAR T-cell therapy) dosing cutoff<30 kg vs ≥30 kg used for dosing: <30 kg up to 12 mg/kg (max 800 mg) OR ≥30 kg up to 8 mg/kg (max 800 mg)
    Pediatric SJIA / PJIA dosing cutoffFor patients <30 kg dosing limits differ by indication (e.g., SJIA/PJIA allow up to 12 mg/kg or 10 mg/kg depending on indication) with the same 800 mg maximum
    Bispecific antibody–associated CRSWeight cutoffs apply for up to four doses during a 1-week approval (see <30 kg vs ≥30 kg rules)
    inv-22: Dosing limits
    Common adult maximum per dose

    Prior Authorization, Step Therapy, and Provider Requirements

    Prior Authorization

    Prior authorization required

    Prior authorization is required for medical benefit coverage of tocilizumab intravenous products; approvals are time-limited and contingent on meeting the indication-specific criteria and dosing. Initial approval requires the medication to be prescribed by or in consultation with a physician who specializes in the condition being treated.

    Prior Authorization

    Indication- and duration-based prior authorization

    Authorization is granted only when the request meets the indication-specific initial or continuation criteria (examples: age thresholds, specialist prescribing/consultation, prior therapy or established duration on therapy, objective measures of response) and dosing limits; approvals are issued for specified durations (e.g., 1 week, 1 month, 6 months, 1 year) depending on the indication.

    Note

    Background and Scope

    Tocilizumab is an interleukin-6 (IL-6) receptor inhibitor with multiple FDA-approved inflammatory and immune-related indications, including cytokine release syndrome (CRS) associated with CAR T-cell therapy, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis / Still's disease, and rheumatoid arthritis. The agent is also listed for several other uses with supportive evidence (e.g., Castleman disease, graft-versus-host disease, immunotherapy-related toxicities, polymyalgia rheumatica) in the policy appendix. Because of the specialized evaluation and monitoring required, initial approvals generally require prescription by or consultation with a specialist in the condition being treated, and prior authorization is required for medical benefit coverage.

    Definitions and Abbreviations

    inv-36: Cytokine Release Syndrome (CRS)
    DefinitionSevere or life-threatening systemic inflammatory response, including that associated with CAR T-cell therapy; tocilizumab is indicated for CRS
    Typical approval durationFor CAR T-cell therapy–associated CRS, approve for 1 week (adequate to receive up to four doses)
    Dosing guidanceFor CRS: <30 kg up to 12 mg/kg (max 800 mg) OR ≥30 kg up to 8 mg/kg (max 800 mg); up to four doses with at least 8 hours between doses
    inv-37: Still's Disease
    Disease conceptStill's disease refers collectively to systemic juvenile idiopathic arthritis (SJIA) and adult-onset Still's disease (AOSD), differing only by age of onset
    Guideline recommendationEULAR/PReS guidelines recommend initiating an IL-1 or IL-6 inhibitor early once diagnosis is established
    Policy Summary
    PayerAspirus Arise
    PolicyInflammatory Conditions Tocilizumab Intravenous Products Utilization Management Medical Policy
    Policy CodePolicy POLIcY: Inflammatory Conditions Tocilizumab Intravenous Products Utilization Management Medical Policy
    Change TypeMaterial revisions and clarifications (age criteria, step therapy documentation, new CRS indication)
    Effective DateJan 1, 2021
    Last ReviewMay 8, 2025
    Next Review DateMay 8, 2025
    Key ActionObtain prior authorization and provide documentation of indication-specific criteria and chart note justification when requesting a non-preferred product.
    SourceLink
    On This Page
    Coverage Criteria and IndicationsCoding, Products, and Dosing InformationPrior Authorization, Step Therapy, and Provider RequirementsBackground and ScopeDefinitions and Abbreviations
    initial 6 months; continuation 1 year

    Initial approval: 6 months. Continuation approval: 1 year if established ≥6 months and response criteria met. Specialist prescribing for continuation may include rheumatology, hepatology, gastroenterology, pulmonology, or oncology.

    Typical maximum: up to 8 mg/kg per dose to a maximum of 800 mg (common across multiple adult indications)
    Pediatric per-dose limitsFor patients <30 kg some indications allow up to 12 mg/kg per dose (max 800 mg); other pediatric indications specify up to 10 mg/kg per dose (max 800 mg)
    Lower maximum for some indicationsPolymyalgia rheumatica dosing limit: up to 6 mg/kg to a maximum of 600 mg per dose
    Dose interval requirementsMinimum intervals vary by indication (examples: ≥8 hours between multiple CRS doses; ≥1 week, ≥2 weeks, or ≥4 weeks between doses depending on indication)

    Appendix reference for prior authorization reviews

    Use the policy appendix to identify agent names, formulations, mechanisms of action, and example inflammatory indications when conducting prior authorization reviews; the appendix is descriptive and does not define single-code authorization rules.

    Step Therapy

    Preferred product step therapy requirements

    Requests for non-preferred products (Actemra, Tofidence) must meet the preferred-product step therapy requirements before authorization will be granted unless a listed exception applies (e.g., not a new start, documented allergy/intolerance, therapeutic failure of preferred products, or diagnosis included only for the non-preferred product).

    • Preferred product: Tyenne; Non-preferred: Actemra, Tofidence
    • Exceptions include: not a new start within prior 365 days; documented allergy/intolerance to preferred products; therapeutic failure of preferred products; diagnosis covered only by non-preferred product
    Step Therapy

    Preferred biosimilar step

    A preferred biosimilar (Tyenne) is designated as the preferred product for patients new to therapy; use of Actemra or Tofidence for patients new to therapy requires demonstration of clinical need and fulfillment of step therapy exceptions.

    • Tyenne is the preferred product for patients new to therapy
    • Policy history documents addition of preferred biosimilar step effective 1/1/2025
    Note

    No step therapy algorithms specified

    No step therapy algorithms or sequencing requirements (beyond the preferred-product exceptions) are specified in the appendix text provided.

    Documentation Required

    Required documentation

    Document indication-specific criteria, prior therapy trials as required by the indication (for example corticosteroids or conventional DMARDs), and that the drug is prescribed by or in consultation with a specialist (rheumatologist, oncologist/hematologist, or other condition specialist as specified).

    • Examples: trial of systemic corticosteroid for polymyalgia rheumatica; trial of one conventional DMARD for rheumatoid arthritis; specialist prescribing/consultation requirement
    Documentation Required

    Step therapy documentation

    For requests to use a non-preferred product in place of the preferred biosimilar (patients new to therapy), include chart note documentation supporting the clinical need for the non-preferred product (e.g., allergy/intolerance, therapeutic failure, or diagnosis-specific rationale).

    • Chart notes must support clinical need for non-preferred product over Tyenne for patients new to therapy
    Note

    Refer to prescribing information

    Refer to each agent's prescribing information for FDA‑approved indications when confirming indication-specific coverage and dosing.

    Denial Risk

    Authorization and step therapy denial risk

    Requests may be denied if prior authorization is not obtained or if step therapy requirements are not met (for example, use of a non-preferred product without meeting the step therapy exceptions or required documentation).

    Denial Risk

    Common denial triggers

    Common triggers for denial include requests for tocilizumab IV for COVID-19 outside the limited hospitalized adults population described in the policy and requests for concurrent use with another biologic or a targeted synthetic oral small molecule for an inflammatory condition.

    • COVID-19: policy does not recommend use except as explicitly described (hospitalized adults meeting specific criteria)
    • Concurrent use with another biologic or targeted synthetic oral small molecule for an inflammatory condition is not recommended and may be denied
    Note

    Appendix descriptive only

    The appendix content is descriptive and reference-only; no additional authorization restrictions are specified in the appendix chunks reviewed.

    Age references in policyPolicy treats SJIA and AOSD together; pediatric SJIA criteria apply to patients ≥2 years and AOSD criteria to adults ≥18 years
    inv-38: Objective measures
    Examples of objective measuresResolution of fever; improvement in rash or organ-specific manifestations; normalization or clinically significant improvement in serum markers (e.g., CRP, ESR, fibrinogen, albumin, hemoglobin, liver function tests)
    Clinical symptom improvementImprovement in at least one symptom compared with baseline (less joint pain/tenderness, stiffness, swelling; decreased fatigue; improved function/ADLs)
    Other measurable improvementsReduction in lymphadenopathy or improved laboratory counts can also be used as objective response measures
    inv-39: Abbreviations
    SCSubcutaneous
    IVIntravenous
    JIAJuvenile idiopathic arthritis
    SJIASystemic juvenile idiopathic arthritis
    PMRPolymyalgia rheumatica